Coagulopathy in COVID-19 is a common presentation in critically ill patients.
The 2019 novel coronavirus has shown phenotypic variability in clinical presentation ranging from completely asymptomatic carriers to critically ill patients with high mortality. Coagulopathy in COVID-19 is a common presentation in critically ill patients. Increased levels of cytokines and chemokines play a major role in coagulopathy. Endothelial inflammation along with formation of microthrombi in major organs has been reported by most of the post mortem studies. Venous thrombosis is a far more common presentation than arterial thrombus even after giving anticoagulant prophylaxis. Major investigations include complete blood count, prothrombin time, activated partial thromboplastin time, fibrinogen, and D-dimer level. Academic societies have given guidelines on management of patients with COVID-19. However, there is still deficiency in understanding the pathogenesis of this disease and therefore, high quality evidence-based studies need to be encouraged.
Full-text chapters of books are available for free to our readers and members of the Royal Society of Chemistry. You need to sign in with your Chemistry World account or with your membership details to gain access. Don't have an account? Register now.
Get access to full-text book chapters. You'll also be able to read more articles each month before you see another paywall. It takes less than a minute and it's completely free.